Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-01 in Non-Proliferative Diabetic Retinopathy (NPDR)
NCT06770933Phase 2Active, not recruiting
- Sponsor
- Vantage Biosciences
- Start
- Feb 2025
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of VX-01, sponsored by Vantage Biosciences. Started Feb 2025; status: active, not recruiting.
02
Drugs
VX-01
Beyond the preview
Go deeper on NCT06770933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770933.